WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Binary Consolidation Sdn Bhd
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Industrial Impact
Sartorius Stedim Biotech | August 09, 2022
Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has agreed to acquire 100 percent of Albumedix Ltd. from private investors. The Nottingham, UK-based company provides best-in-class recombinant albumin-based solutions. Recombinant human albumin is an important component for the biopharmaceutical industry required for various applications, for example as an animal-free additive to cell culture media and for the stabilization of vaccines and viral therapi...
Industry Outlook
Globenewswire | June 20, 2023
Culture Biosciences and Cytiva are collaborating to advance innovation in upstream bioprocessing by providing customers greater access to predictive and robust scale-up capabilities. Together, Cytiva and Culture Biosciences aim to bring to customers new bioprocess solutions that use digitization, in-silico approaches, and virtual monitoring and control of experiments. “Cytiva is excited to work with Culture Biosciences to help customers gain confidence that the process and...
Cell and Gene Therapy
Sphere Fluidics | October 29, 2021
Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million investment round. The round was led by Sofinnova Partner and Redmile Group investing on equal terms. Sphere Fluidics will use the funding to enable the expansion of the Company’s international sales activities in key markets and improving its support for customers. Furthermore...
AI, Industrial Impact
Cimeio | December 12, 2022
The two studies demonstrate proof-of-concept that genetically engineered variants of cell surface receptors harboring single amino acid substitutions are fully functional but evade a paired immunotherapy directed against the wild-type molecule. This technology will enable the development of more efficient and safer targeted conditioning regimens for hematopoietic stem cell transplantation, gene therapies, and opens the path to more efficient cell and immunotherapy-based treatment approaches for ...
Medical
Whitepaper
Video
Medical, Industry Outlook
Research, Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE